scholarly journals Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer

2017 ◽  
Vol 14 (2) ◽  
pp. 2491-2498 ◽  
Author(s):  
Ka-Rham Kim ◽  
Jung-Hwan Yoon ◽  
Hyun-Jeong Shim ◽  
Jun-Eul Hwang ◽  
Woo-Kyun Bae ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Depth Of Response ◽  
Mthfr Genotype

The Role of Maintenance Therapy in Metastatic Colorectal Cancer

JAMA Oncology ◽  
2020 ◽  
Vol 6 (6) ◽  
pp. 937
Author(s):  
Zi-Xian Wang ◽  
Fei Liang ◽  
Rui-Hua Xu
Keyword(s):  
Colorectal Cancer ◽  
Maintenance Therapy ◽  
Metastatic Colorectal Cancer

scholarly journals Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer

BJS Open ◽  
2018 ◽  
Vol 3 (1) ◽  
pp. 95-105 ◽  
Author(s):  
C. H. A. Lee ◽  
S. Wilkins ◽  
K. Oliva ◽  
M. P. Staples ◽  
P. J. McMurrick
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Metastatic Colorectal Cancer ◽  
Lymph Node Ratio ◽  
Lymph Node Yield ◽  
Node Ratio ◽  
Node Yield

Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer

2013 ◽  
Vol 70 (21) ◽  
pp. 1887-1896 ◽  
Author(s):  
Clement Chung ◽  
Nisha Pherwani
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Performance Status ◽  
Angiogenesis Inhibitor ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Second Line ◽  
Patient Response ◽  
Line Setting

Abstract Purpose The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of ziv-aflibercept in combination therapy for metastatic colorectal cancer (mCRC) are reviewed. Summary Ziv-aflibercept (Zaltrap, Regeneron Pharmaceuticals and sanofi-aventis) is a novel recombinant fusion protein that targets the angiogenesis signaling pathway of tumor cells by blocking vascular endothelial growth factor (VEGF) receptors that play a key role in tumor growth and metastasis; it is a more potent VEGF blocker than bevacizumab. Ziv-aflibercept is approved by the Food and Drug Administration for use in combination with fluorouracil, irinotecan, and leucovorin (the FOLFIRI regimen) for second-line treatment of patients with mCRC who have disease progression during first-line oxaliplatin-based chemotherapy. A Phase III trial demonstrated that relative to FOLFIRI therapy alone, the use of ziv-aflibercept was associated with significantly improved patient response, overall survival, and progression-free survival in patients with good performance status at baseline, including some who had received prior bevacizumab therapy. The most common grade 3 or 4 adverse effects associated with ziv-aflibercept use in clinical studies were neutropenia, hypertension, and diarrhea; the U.S. product labeling warns of potential hemorrhage and other treatment-related risks. Conclusion Current clinical data are insufficient to directly compare ziv-aflibercept and bevacizumab when used with standard combination chemotherapy as first- or second-line regimens for mCRC. The role of ziv-aflibercept is currently limited to the second-line setting in combination with irinotecan-based regimens in mCRC patients who have not received irinotecan previously. The role of ziv-aflibercept in chemotherapy for other tumor types is yet to be determined.

scholarly journals The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report

2020 ◽  
Vol Volume 13 ◽  
pp. 11849-11853
Author(s):  
Zhan Wang ◽  
Chen-Yang Ye ◽  
Wen-Li Zhou ◽  
Miao-Miao Wang ◽  
Wei-Ping Dai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Braf V600e ◽  
Combination Therapies
Sign in / Sign up

Export Citation Format

Share Document